Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05VVX
|
|||
| Former ID |
DCL000203
|
|||
| Drug Name |
PTC299
|
|||
| Synonyms |
6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [1], [2] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [3] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
PTC Therape
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H20Cl2N2O3
|
|||
| Canonical SMILES |
COC1=CC=C(C=C1)C2C3=C(CCN2C(=O)OC4=CC=C(C=C4)Cl)C5=C(N3)C=CC(=C5)Cl
|
|||
| InChI |
1S/C25H20Cl2N2O3/c1-31-18-7-2-15(3-8-18)24-23-20(21-14-17(27)6-11-22(21)28-23)12-13-29(24)25(30)32-19-9-4-16(26)5-10-19/h2-11,14,24,28H,12-13H2,1H3/t24-/m0/s1
|
|||
| InChIKey |
SRSHBZRURUNOSM-DEOSSOPVSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
598789, 5608482, 8153212, 14849428, 24724598, 26759537, 29224284, 46515156, 48259039, 50070403, 50071047, 52036560, 56365850, 57322665, 85787195, 99302832, 103142222, 103303420, 104308628, 117511046, 121366705, 124349762, 129824040, 134338870, 134340535, 134341360, 135029412, 137092526, 139404114, 162149644, 162247947, 162905288, 163395039, 163687318, 163843810, 175607510, 176485412, 178102662, 179148821, 201507296, 223540967, 224815350, 226513016, 234840306
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6040). | |||
| REF 2 | The effects of antiinflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A. Inflamm Res. 1995 Jul;44(7):269-74. | |||
| REF 3 | ClinicalTrials.gov (NCT00911248) PTC299 for Treatment of Neurofibromatosis Type 2. U.S. National Institutes of Health. | |||
| REF 4 | Therapeutic intervention in a rat model of ARDS: I. Dual inhibition of arachidonic acid metabolism. Circ Shock. 1990 Nov;32(3):231-42. | |||
| REF 5 | Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.